FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 104 filers reported holding FATE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.33 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $997,000 | +23.5% | 64,186 | +61.4% | 0.05% | +20.9% |
| Q2 2019 | $807,000 | +15.5% | 39,770 | 0.0% | 0.04% | +19.4% |
| Q1 2019 | $699,000 | -13.9% | 39,770 | -37.2% | 0.04% | -23.4% |
| Q4 2018 | $812,000 | -12.2% | 63,325 | +11.6% | 0.05% | +17.5% |
| Q3 2018 | $925,000 | +40.6% | 56,760 | -2.2% | 0.04% | +150.0% |
| Q2 2018 | $658,000 | +31.1% | 58,030 | +12.8% | 0.02% | +23.1% |
| Q1 2018 | $502,000 | – | 51,460 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
| Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
| Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
| Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
| DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
| Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
| Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
| Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
| Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |